Europe Skin Cancer Diagnostics Market to Grow at a CAGR of 6.5% to reach US$ 1,375.9 million from 2021 to 2028

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Europe Skin Cancer Diagnostics Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Europe Skin Cancer Diagnostics Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1
5.1.2 Increasing incidence of skin cancer
5.1.3 Advancements in diagnostic technologies
5.1.4 Rising awareness about early detection
5.1.5 Growing demand for non-invasive diagnostic methods
5.1.6 Expanding geriatric population
5.1.7 Enhanced healthcare infrastructure
5.1.8 Increasing preference for personalized medicine
5.1.9 Integration of AI and machine learning in diagnostics
5.1.10 Development of portable and cost-effective diagnostic tools
5.1.11 Government initiatives for skin cancer prevention and detection
5.1.12 Rising disposable incomes in emerging markets
5.1.13 Growing healthcare expenditure

5.2 Market Opportunities

5.2.1
5.2.2 Emerging markets with growing healthcare access
5.2.3 Development of AI-powered diagnostic tools
5.2.4 Expansion of telemedicine for remote skin cancer diagnosis
5.2.5 Advancements in wearable diagnostic devices
5.2.6 Increasing demand for home-based diagnostic solutions
5.2.7 Integration of genomic testing in diagnostics
5.2.8 Collaborations between tech and healthcare companies
5.2.9 Rising popularity of skin cancer awareness programs
5.2.10 Growth in personalized treatment options
5.2.11 Expanding adoption of non-invasive diagnostic techniques
5.2.12 High potential for diagnostic innovations in photonics and imaging
5.2.13 Government funding for skin cancer research and early detection

5.3 Future Trends

5.3.1
5.3.2 Integration of artificial intelligence for enhanced accuracy
5.3.3 Growth of AI-based teledermatology platforms
5.3.4 Shift toward personalized and precision diagnostics
5.3.5 Increasing use of molecular and genetic biomarkers
5.3.6 Rise of portable and handheld diagnostic devices
5.3.7 Expansion of wearable skin cancer detection technology
5.3.8 Advancements in real-time, in-situ diagnostic tools
5.3.9 Development of AI-driven mobile apps for early detection
5.3.10 Rising adoption of minimally invasive diagnostic procedures
5.3.11 Integration of multi-modal diagnostic approaches
5.3.12 Growing use of 3D imaging and spectral analysis
5.3.13 Collaboration between dermatologists and tech companies for innovation

5.4 Impact of Drivers and Restraints

6. Europe Skin Cancer Diagnostics Market Regional Analysis

6.1 Europe Skin Cancer Diagnostics Market Overview

6.2 Europe Skin Cancer Diagnostics Market Revenue 2019-2028 (US$ Million)

6.3 Europe Skin Cancer Diagnostics Market Forecast Analysis

7. Europe Skin Cancer Diagnostics Market Analysis – by Type

7.1 Melanoma and Non-Melanoma

7.1.1 Overview
7.1.2 Melanoma and Non-Melanoma: Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Skin Cancer Diagnostics Market Analysis – by Screening Type

8.1 Blood Tests

8.1.1 Overview
8.1.2 Blood Tests: Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

8.2 Dermatoscopy

8.2.1 Overview
8.2.2 Dermatoscopy: Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

8.3 Imaging Tests

8.3.1 Overview
8.3.2 Imaging Tests: Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Lymph Node Biopsy

8.4.1 Overview
8.4.2 Lymph Node Biopsy: Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

8.5 Skin Biopsy

8.5.1 Overview
8.5.2 Skin Biopsy : Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

9. Europe Skin Cancer Diagnostics Market – Europe Analysis

9.1 Europe

9.1.1 Europe Skin Cancer Diagnostics Market Breakdown, by Key Country, 2022 and 2028 (%)
9.1.1.1 Europe Skin Cancer Diagnostics Market – Revenue and Forecast Analysis – by Country
9.1.1.1 UK: Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

9.1.1.1.1 UK: Europe Skin Cancer Diagnostics Market Breakdown, by Type
9.1.1.1.2 UK: Europe Skin Cancer Diagnostics Market Breakdown, by Screening Type

9.1.1.2 Germany: Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

9.1.1.2.1 Germany: Europe Skin Cancer Diagnostics Market Breakdown, by Type
9.1.1.2.2 Germany: Europe Skin Cancer Diagnostics Market Breakdown, by Screening Type

9.1.1.3 France: Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

9.1.1.3.1 France: Europe Skin Cancer Diagnostics Market Breakdown, by Type
9.1.1.3.2 France: Europe Skin Cancer Diagnostics Market Breakdown, by Screening Type

9.1.1.4 Russia: Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

9.1.1.4.1 Russia: Europe Skin Cancer Diagnostics Market Breakdown, by Type
9.1.1.4.2 Russia: Europe Skin Cancer Diagnostics Market Breakdown, by Screening Type

9.1.1.5 Italy: Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

9.1.1.5.1 Italy: Europe Skin Cancer Diagnostics Market Breakdown, by Type
9.1.1.5.2 Italy: Europe Skin Cancer Diagnostics Market Breakdown, by Screening Type

9.1.1.6 Rest of Europe: Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

9.1.1.6.1 Rest of Europe: Europe Skin Cancer Diagnostics Market Breakdown, by Type
9.1.1.6.2 Rest of Europe: Europe Skin Cancer Diagnostics Market Breakdown, by Screening Type

10. Competitive Landscape

10.1 Heat Map Analysis

10.2 Company Positioning and Concentration

11. Europe Skin Cancer Diagnostics Market Industry Landscape

11.1 Overview

11.2 Mergers and Acquisitions

11.3 Agreements, Collaborations, and Joint Ventures

11.4 New Product Launches

11.5 Expansions and Other Strategic Developments

12. Company Profiles

12.1 SkylineDx BV

12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments

12.2 AMLo Biosciences Limited

12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments

12.3 DermLite LLC

12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments

12.4 NeraCare GmbH

12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments

12.5 F. HOFFMANN-LA ROCHE LTD

12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments

12.6 bioMerieux SA

12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments

12.7 Michelson Diagnostics Ltd.

12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments

13. Appendix

13.1 About Business Market Insights